TARGETING THE NOCICEPTIN/ORPHANIN FQ RECEPTOR FOR SCLERODERMA THERAPY

$174,946FY2015Department of the ArmyDOD

Palo Alto Veterans Institute For Research, Palo Alto

Investigators